Gefitinib (Iressa) trials in non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Lung Cancer

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0169-5002(03)00136-3PMID 12867059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor family in lung cancer and premalignancy.

  2002cited by this paper
• Treatment of advanced non-small-cell lung cancer with two-drug combinations.

  2002cited by this paper
• Influence of unrecognized molecular heterogeneity on randomized clinical trials.

  2002cited by this paper
• Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

  2002cited by this paper
• Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

  2002cited by this paper
• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  2002cited by this paper
• Evaluation of response: new and standard criteria.

  2002cited by this paper
• Randomized discontinuation design: application to cytostatic antineoplastic agents.

  2002cited by this paper
• Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1)

  2002cited by this paper
• Clinical trial designs for cytostatic agents.

  2001cited by this paper
• Tyrosine kinase inhibitors—ZD1839 (Iressa)

  2001cited by this paper
• Clinical trial designs for cytostatic agents: are new approaches needed?

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

  2000cited by this paper
• Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

  2000cited by this paper
• Jeremiah Metzger Lecture. Targeted cancer therapy.

  2000cited by this paper
• Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

  1998cited by this paper
• Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.

  1997cited by this paper
• Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype.

  1995cited by this paper
• Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

  1993cited by this paper
• Epidermal growth factor-receptor-protein kinase interactions.

  1981cited by this paper
• Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity.

  1980cited by this paper
• Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

  1962cited by this paper
• Overexpression of the Epidermal Growth Factor Receptor and Its Ligand Transforming Growth Factor a Is Frequent in Resectable Non-small Cell Lung Cancer but Does Not Predict Tumor Progression' Egfr and Tgf-a Overexpression Was Observed in All Tumor

  year unknowncited by this paper

• Synthesis and evaluation of methoxyquinazoline sulfonamide derivatives as bifunctional molecular targeting tumor related inflammation and anti-EGFR triple-mutation.

  2026cites this paper
• Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia

  2022cites this paper
• Clinical development of targeted and immune based anti-cancer therapies

  2019cites this paper
• Epidermal growth factor receptor inhibitor induces Interleukin-6 via NADPH oxidase enzymes in head and neck cancer cells

  2012cites this paper
• Cryoablation Combined with Molecular Target Therapy Improves the Curative Effect in Patients with Advanced Non-Small Cell Lung Cancer

  2011cites this paper
• Small cell lung cancer.

  2008cites this paper
• Les thérapeutiques ciblées en association avec la radiothérapie dans le cancer bronchique

  2007cites this paper
• Targeted therapies for non-small cell lung cancer.

  2007cites this paper
• Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.

  2007cites this paper
• [Targeted therapies and radiotherapy in lung cancer].

  2007cites this paper
• Tyrosine kinase inhibitors and cancer therapy.

  2007cites this paper
• EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

  2006cites this paper
• Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.

  2006cites this paper
• Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer

  2006cites this paper
• Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies

  2006cites this paper
• A Review of First-Line Treatment for Small-cell Lung Cancer

  2006cites this paper
• EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer

  2006cites this paper
• Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure?

  2006cites this paper
• Challenges and opportunities of pharmacogenetics in drug development.

  2006cites this paper
• Suramin as a chemo- and radio-sensitizer: preclinical translational studies

  2006cites this paper
• Einfluss des Tyrosinkinaseinhibitors ZD1839 (Iressa®) als Monotherapie und in Kombination mit hyperfraktionierter Bestrahlung auf die Proliferation von high-grade Gliomen in vitro unter Berücksichtigung der Expression des membranständigen EGF-Rezeptors

  2006cites this paper
• Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa®)

  2005cites this paper
• HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.

  2005cites this paper
• Tyrosinkinaseinhibitoren und monoklonale Antikörper

  2005cites this paper
• Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.

  2005cites this paper
• Erlotinib in the treatment of non-small cell lung cancer

  2005cites this paper
• Novel strategies for the early detection and prevention of lung cancer.

  2005cites this paper
• Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

  2005cites this paper
• Docetaxel for Metastatic Cancer and Its Role in Combination Therapies for Advanced Prostate Cancer

  2005cites this paper
• Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis

  2005cites this paper
• Small Cell Lung Cancer − RNA in Non Therapeutic Inhibition with SU 11274 and Small Interfering Functional Expression and Mutations of c-Met and Its

  2005cites this paper
• Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

  2005cites this paper
• Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.

  2005cites this paper
• Les thrapeutiques cibles en oncologie thoracique

  2004cites this paper
• Surgical treatment of T3 and T4 non-small cell lung cancer

  2004cites this paper
• Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.

  2004cites this paper
• Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer.

  2004cites this paper
• Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition

  2004cites this paper
• Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done

  2004cites this paper
• Signal transduction pathways as novel therapy targets in lung cancer.

  2004cites this paper
• Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results.

  2004cites this paper
• Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.

  2004cites this paper
• In relation to Anninga et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.

  2004cites this paper
• Receptor Tyrosine Kinases and Inhibitors in Lung Cancer

  2004cites this paper
• Growth factor signaling and resistance to cancer chemotherapy.

  2004cites this paper
• Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development

  2004cites this paper
• The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model

  2004cites this paper
• Molecular targeting in radiotherapy of lung cancer.

  2004cites this paper
• Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

  2004cites this paper
• Recent advances in management of small-cell lung cancer.

  2004cites this paper
• The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer.

  2003cites this paper